secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001558370-22-015982
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos Q3 net loss $27.6M ($0.58 EPS); revenue down 4.6% YoY to $71.3M; raises 2022 sales outlook
--------------------------------------------------------------------------------

- Net sales $71.3M, down 4.6% reported (1.6% constant currency) vs $74.7M in Q3 2021.
- Net loss $27.6M ($0.58 diluted) vs net income $6.2M ($0.13) in prior year, which included $30M litigation settlement.
- Non-GAAP net loss $21.3M ($0.45) vs non-GAAP net loss $14.7M ($0.31) in Q3 2021.
- Updated 2022 net sales guidance to $278-280M from prior $275-280M; cash and investments $371M.
- Glaucoma net sales $53.7M, Corneal Health $17.5M; GAAP gross margin 76%, non-GAAP 84%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/0001558370-22-015982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/gkos-20221102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-015982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer